文献速递妇科

既往有资格接种人乳头瘤病毒疫苗的出生队列中阴道镜检查的表现

Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
PubMed 文献 · Am J Obstet Gynecol · 2021-12-23

瑞典一项出生队列研究比较接种与未接种人乳头瘤病毒疫苗女性进入宫颈筛查项目后阴道镜评估的表现,发现两组阴道镜评估无统计学显著差异,但接种组人乳头瘤病毒16/18型感染率显著降低。

要点

  • 接种组人乳头瘤病毒16/18型阳性率为5%(7/90),未接种组为33%(23/70),P<.001。
  • 两组高级别病变检出率分别为37%(33/90)和40%(28/70),P=.697,无统计学显著差异。
  • 阴道镜检出高级别鳞状上皮内病变的敏感性在未接种组略高,但差异无统计学意义。

核心结论

  • 接种与未接种人乳头瘤病毒疫苗女性的阴道镜评估无统计学显著差异,尽管接种降低了人乳头瘤病毒16/18型感染率。
  • 结果表明阴道镜检查在进入 organized 宫颈筛查项目的接种女性中仍是有用工具。

研究设计与样本

  • 研究纳入瑞典一个地区1994和1995年出生、23岁进入宫颈筛查项目的女性。
  • 筛查阳性后2至4个月内按国家指南行阴道镜检查,采用Swede评分和阴道镜印象评估。
  • 对阴道镜病灶行点活检,无病灶时行随机活检,作为金标准;行宫颈管内取样检测14种高危人乳头瘤病毒基因型。
  • 所有阴道镜图像数字保存供复审;通过链接国家疫苗接种登记获取接种状态。
  • 2018和2019年,165例筛查阳性女性中160例(98%)接受阴道镜检查,其中90例(56%)接种疫苗,70例(44%)未接种。

主要发现

  • 接种组人乳头瘤病毒16/18型阳性7/90(5%),未接种组23/70(33%),P<.001。
  • 高级别病变共61/160(38%),接种组33/90(37%),未接种组28/70(40%),P=.697。
  • 高级别鳞状上皮内病变中Swede评分6至10分者,接种组64%(21/33),未接种组75%(21/28),P=.124。
  • 检测高级别鳞状上皮内病变的敏感性:Swede评分接种组0.67 vs 未接种组0.75;阴道镜印象接种组0.67 vs 未接种组0.68,差异无统计学意义。

关键数值与推荐

  • Swede评分6至10分提示高级别鳞状上皮内病变。
  • 人乳头瘤病毒检测覆盖14种高危基因型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sweden started subsidized quadrivalent human papillomavirus vaccination for girls aged 13 to 17 in 2007. Since 2012, vaccination has been offered to all girls aged 10 to 12 within a school-based vaccination program, with a coverage of 80% or more. In addition, the vaccine has been offered on-demand as catch-up vaccination for girls aged 13 to 18, with a cumulative coverage of 55% to 60%. Since the first women in Sweden eligible for human papillomavirus vaccination entered the cervical screening program, questions on how to evaluate colposcopic findings among vaccinated women have arisen. Evidence is inconsistent on whether colposcopic features for the detection of cervical lesions are influenced by specific human papillomavirus genotypes and what role they can play in the prevention of invasive cervical cancer in vaccinated women. OBJECTIVE: The primary objective of the study was to compare colposcopic evaluation in vaccinated and unvaccinated women entering the organized cervical screening program. STUDY DESIGN: Women in the 1994 and 1995 birth cohorts who entered the cervical screening program at age 23 in 1 region in Sweden were identified. Colposcopy was performed within 2 to 4 months after a positive screening result in accordance with national guidelines. Colposcopic performance was evaluated according to national guidelines with the Swede score and colposcopic impression. Punch biopsies were taken from colposcopic lesions and as "random biopsies" in the absence of lesions. These biopsies were used as the gold standard for the analysis. An endocervical sample was analyzed for cytologic findings and detection of 14 high-risk human papillomavirus genotypes. All colposcopic imaging was saved digitally for re-review. Vaccination status was obtained through linkage to national vaccination registries. Results were compared between vaccinated and unvaccinated women. RESULTS: In 2018 and 2019, 160 out of 165 (98%) women with a positive screening result attended colposcopy, of which 90 (56%) were vaccinated and 70 (44%) were unvaccinated. Only 7 out of 90 (5%) women in the vaccinated group were human papillomavirus 16/18-positive, compared with 23 out of 70 (33%) in the unvaccinated group (P<.001). There was a total of 61 out of 160 (38%) women with high-grade lesions-33 out of 90 (37%) in the vaccinated group and 28 out of 70 (40%) in the unvaccinated group (P=.697). There was 64% (21/33) of vaccinated women and 75% (21/28) of unvaccinated women with high-grade squamous intraepithelial lesions who had a Swede score of 6 to 10 (indicating high-grade squamous intraepithelial lesions) (P=.124). The sensitivity was slightly higher for the detection of high-grade squamous intraepithelial lesions in unvaccinated women using both colposcopic tests (Swede score, 0.67 vs 0.75; colposcopic impression, 0.67 vs 0.68), but the difference was not statistically significant. CONCLUSION: We found no statistically significant difference between the colposcopic evaluation of vaccinated and unvaccinated women, although human papillomavirus vaccination reduced the prevalence of human papillomavirus 16/18 infection in human papillomavirus-vaccinated women. Our results indicate that colposcopic examination is still a useful tool in vaccinated women entering the organized cervical screening program.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sahlgren HAI, Elfgren K, Sparen P, et al. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination. Am J Obstet Gynecol. 2021. PMID: 34954217. doi:10.1016/j.ajog.2021.11.1372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。